A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV
Status:
Completed
Trial end date:
2020-02-10
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label,randomized, multiple dose, varied administration regimen study
with 2 parts (Parts A and B) in Subjects Infected with Chronic Hepatitis B Virus
Phase:
Phase 2
Details
Lead Sponsor:
F-star Therapeutics, Inc. Spring Bank Pharmaceuticals, Inc.